Search PubMed⌕ Search

Biomedical subjects

G Metz

Publications and source records attributed to G Metz.

At least 55 records · Page 3Linked to original sources
PubMed1980

[Cutaneous histiocytosis X].

Histiocytosis X comprises three clinical entities whose common substrate is a localized or systemic proliferation of atypical histiocytes. On the basis of the age of manifestation, acuity of the clinical course and organ involvement Abt-Letterer-Siwe's disease, Hand-Schüller-Christian's disease and eosinophilic granuloma can be differentiated from each other, although transitional varieties of these syndromes are possible. Not infrequently oligosymptomatic forms are misinterpreted, especially when the skin is the only involved organ. In the following case report cutaneous histiocytosis X will be discussed in terms of its clinical expression. Electron-microscopy has proved to be the best methods to make the diagnosis of such atypical cases.

Aged↗
PubMed1980

[Chemistry of phenoxyacetic acid esters of oxyalkyltheophyllines and 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methyl-propionate] (etofylline clofibrate), a novel antilipaemic agent (author's transl)].

Esters of phenoxyacetic acids and oxyalkyltheophyllines were prepared as potential antihyperlipaemics. The basic idea was to ameliorate the known antilipaemic potency of phenoxyacetic acids and that of clofibric acid as the best known representative, respectively, by using alcoholic ester components with therapeutical efficacy of their own and to expand their therapeutical spectrum. Syntheses and preparative routes of these esters are presented. 1-(Theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methyl-propionate] (ML 1024; etofylline clofibrate; Duolip) was selected for further investigations. Characteristics and spectroscopic data of ML 1024 are described.

Chemical Phenomena↗
PubMed1980

Hypolipaemic activity of 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate) and its analogues in normolipaemic rats.

The hypolipaemic potential of 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate, ML 1024, Duolip) was assessed in conjunction with a series of analogous new theophylline derivatives and clofibrate (CPIB) by a short-term screening test in normolipaemic rats. The significant cholesterol and triglyceride-lowering effect of ML 1024 was comparable to that observed for CPIB over the 50-300 mg/kg dose range evaluated and contrasted with the relative inactivity associated with its chemical analogues.

Animals↗
PubMed1980

[Evaluation of the antilipaemic potential of etofylline clofibrate, its metabolites and clofibrate in dietary-induced hyperlipidaemia in the rat (author's transl)].

Efficacy of 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate, ML 1024, Duolip) and its molecule components (metabolites) of structurally similar theophylline esters and of clofibrate as standard was investigated in the artificial hyperlipidaemia of the rat. In accordance with former results etofylline clofibrate was antilipaemically active and, in contrast to similar esters and clofibrate, significantly decreased the cholesterol level. An investigation of the efficacy of its metabolites, either alone or in equivalent mixture, as well as of the standard clofibrate under fat diet demonstrated low efficacy of etofylline, but an increased activity in combination with clofibrate or clofibric acid. The activity of the combination is significantly superior to that of clofibrate under fat diet, but not under normal diet. The increased efficacy of etofylline clofibrate is undoubtedly an unusual potentiation, an additive effect of the metabolites can be excluded. Cholesterol and triglycerides are relevant parameters for the experimental evaluation of the efficacy. Measurement of total lipids offers no additional information. Substitution of triglycerides by total-beta-lipoproteins as parameter seems methodically useful, since values of cholesterol, triglycerides and beta-lipoproteins correlate well under normal diet.

Animals↗
PubMed1980

Effect of etofylline clofibrate on experimental thrombosis and platelet function.

1-(Theophyllin-7yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate, ML 1024, Duolip) was shown to be a potent inhibitor of experimental thrombus formation in the microvasculature of the hamster cheek pouch and of platelet aggregation and adhesiveness in the cynomolgus monkey. Inhibitory effect on thrombus formation was superior to that obtained with either of the molecule components (clofibric acid and etofylline) or their 1 : 1 mixture and a synergistic effect was apparent. Etofylline clofibrate was more active than a commercial antithrombotic drug combination of acetylsalicylic acid (ASA) and dipyridamole as an inhibitor of thrombus formation in this test system (p less than 0.05) at the proposed therapeutic dose level for each drug. In the cynomolgus monkey, etofylline clofibrate was shown again to be a potent inhibitor of platelet aggregation induced by ADP and collagen and of platelet adesiveness after administration of 12 mg/kg/day for 21 days. A mixture of clofibrate and etofylline (21.25 mg/kg/day and 3.75 mg/kg/day, respectively) had relatively less effect on platelet aggregation and no consistent effect on platelet adhesiveness. The activity found in both test systems indicates a promising antithrombotic potential for etofylline clofibrate and warrants further investigation in humans.

Animals↗
PubMed1980

[Clinical effects and tolerance of etofylline clofibrate].

The efficacy of 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate, Duolip) was investigated in 47 hyperlipidaemic patients of type II--V in an open within-patient study. All patients were dietary adapted before the preliminary wash-out period of 4 weeks and received etofylline clofibrate in a dosage of 500 mg/day (2x1 capsule) over 4 weeks, and 750 mg/day (3 x 1 capsule) over further 4 months. Depending on type reductions of cholesterol between 15 and 23% and of triglycerides between 24 and 52% were achieved. The total lipids were reduced, too, between 14 and 31%. Except for type IIb, all reductions were statistically significant. The rate of responders was between 47 and 80%. The higher dose (750 mg) only affected the cases of type III and IV, in which a higher rate of responders was found coinciding with more pronounced lipid level reductions. However, the influence of the treatment duration on this increased activity may play an important role. Etofylline clofibrate did not show any side effects and was well tolerated. This clinical finding coinciding with the results of the preceding pilot study on the human tolerability in 10 volunteers. From all parameters tested only GPT and cholesterol showed significant alterations (reduction).

Clofibrate↗
PubMed1979

[Naevus spongiosus albus mucosae. Review and personal observations].

White sponge nevus of the mucosa is a rare, mostly verifiable hereditary ectodermal dysplasia of the mucous membranes. Because associated symptoms of the skin are missing, it is classified as a distinctive disease among the congenital leukokeratoses. In the most cases the symptomless mucosal lesions are detected by dentological examination though they are present at birth or appear in the first years of life. On the basis of three own observations clinical appearance, histopathology, electronmicroscopy and differential diagnosis are discussed.

Child↗
PubMed1978

[Relative bioavailability of a vincamine retard formulation. Pharmacokinetic study in normal subjects (author's transl)].

The study was carried out in 6 healthy volunteers in cross-over design. The pharmacokinetic parameters were calculated after application of 60 mg vincamine base in comparison to a sustained release formulation (vincamine ratio-pharm 30 mg) on the basis of a GC method. Summarizing it can be stated that the sustained release formulation has a flatter profile and is therefore more adapted to clinical application. The extent of absorption expressed as AUC of the serum concentration-time curve, has three times the extent of the curve with the pure substance.

Biological Availability↗
PubMed1978

[Juvenile dermatofibrosarcoma protuberans].

Dermatofibrosarcoma protuberans is observed in younger or middle-aged patients after the transformation from the initial stage of a chronic fibrous plaque into a rapidly growing, sometimes painful or bleeding tumor. First manifestation in early childhood is considered in about 10 per cent of the reported patients. In the case that we observed the neoplasma was present at birth and increased to a multinodular tumor between three and four years of age. Repeated local recurrences in the scar were observed after the surgical removal. The clinical behavior of the tumor in childhood is comparable to those of adults. Because of its malignant potential extended early excision should be undertaken despite of the risk of widespread scarring.

Child↗
PubMed1978

[Nevoid hair bundles in man].

Between the different forms of multiple hairs the circumscribed occurence of compound hairs is a rare nevoid hair-abnormality. It is caused by merging of several follicles in the middle or upper corium. The deep parts and the papillae are independent units. The pathogenesis, clinical relevance and therapy of compound hairs are discussed on the basis of an own observation.

Adult↗
PubMed1977

Breath-methane in patients with cancer of the large bowel.

In 30 patients with cancer of the large bowel, 24 (80%) had detectable levels of methane in their breath, compared with 25 (39%) of 64 patients with non-malignant large-bowel disease and 83 (40%) of 208 subjects without large-bowel disease. These findings suggest that there may be a difference in anaerobic intestinal flora between patients with cancer of the large bowel and those without the disease. This difference may antedate the development of the tumour or, alternatively, result from the tumour.

Aged↗
PubMed1977

1-(Theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (ML 1024), a new hypolipemic agent.

1-(Theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (ML 1024) was tested on acute and chronic toxicity, on teratogenesis and fetotoxicity, on blood pressure and blood flow behaviour, on hypolipemic activity and general pharmacological behaviour in a screening test using 54 parameters. Results warrant further investigation of the potential therapeutic application of ML 1024 in humans based on its superiority to the well-known antilipemic clofibrate (CPIB).

Animals↗
PubMed1977

Hypolipemic activity of clofibrate-related compounds. 2nd Communication.

Clofibrate-related compounds were synthesized from substituted phenoxyacetic acids by esterification with salicylic acid derivatives, by amidation of thiazolidines or by reaction with cinnarizine. Lipid lowering effect was investigated in normolipemic and hyperlipemic rats. The long-term hyperlipemic model used permits differentiation of hypolipemic efficacy, i.e., from clofibrate or compounds of similar activity.

Animals↗
PubMed1977

Effect of dietary fiber on complications of gastric surgery: prevention of postprandial hypoglycemia by pectin.

The dumping syndrome is a very troublesome problem to some patients after gastric surgery. Gel-forming carbohydrates have recently been used to modify glucose absorption. The addition of 14.5 g of pectin to a 50-g oral glucose load prevented the occurrence of hypoglycemic symptoms and maintained the blood glucose levels above control values by 64% at 90 min (P less than 0.002) and 46% at 120 min (P less than 0.01) in postgastric surgery patients whose 120-min values after 50 g of glucose alone had fallen below 50 mg per 100 ml (2.8 mmoles per liter). Breath H2 production, used as an index of bacterial fermentation of glucose, was abolished or reduced by pectin in all 5 cases in which this had previously occurred. A trial of 10 g of pectin per day prevented recurrent postprandial hypoglycemic attacks in the most severely affected individual. Pectin and perhaps other unabsorbable polysaccharides are likely to prove useful in the treatment of abnormal carbohydrate absorption after gastric surgery.

Adult↗